Mounjaro before and after: what to expect month by month, according to the trials

You may start to notice Mounjaro within the first few weeks, but it does not deliver its final result in a month. In trials and in clinical practice, weight loss with tirzepatide tends to be gradual: some loss may already be visible in the first 4 weeks, and in one real-world study the average change was −5.9% at around 3 months, −10.1% at 6 months and −15.3% at 12 months.

In Spain, Mounjaro is authorised for type 2 diabetes and for weight management in adults with obesity, or with overweight and at least one weight-related comorbidity. Specifically, the Spanish summary of product characteristics (SmPC) lists it for adults with a starting BMI of ≥30 kg/m², or of ≥27 to <30 kg/m² with at least one weight-related comorbidity.

How long does Mounjaro take to work?

The Spanish SmPC describes tirzepatide as a long-acting agonist of the GIP and GLP-1 receptors. According to that document, it reduces energy intake and appetite, increases satiety and fullness, and slows gastric emptying, particularly at the start. This helps explain why some people notice changes early on, even though the pace is not the same for everyone.

The first month usually corresponds to the starting dose of 2.5 mg once a week for 4 weeks. This phase is used to step the dose up gradually, not as a maintenance dose, so a modest response at first does not allow any firm conclusions about the final result.

The regulatory charts from SURMOUNT-1 show weight loss within the first 4 weeks, but still well short of the average loss seen by the end of the study. If you would like more background on this type of treatment, you may find it helpful to read what GLP-1 agonists are and how they work in obesity.

What results to expect month by month, according to the studies

First month

Expect a starting point, not a finish line. During those first 4 weeks the approved dosing schedule keeps you on 2.5 mg a week, and the regulatory data show that weight loss can already occur in that period. What matters here is the direction of travel, not expecting in a single month the result that the trials assessed many months later.

Around 3 months

In a real-world comparative study published in 2024, the average weight change with tirzepatide was −5.9% at 3 months. It is a useful figure for setting expectations, but it is not a promise for any individual and it does not replace what was seen in controlled trials.

Around 6 months

In the same observational study, the average was −10.1% at 6 months. In addition, a SURMOUNT-1 analysis of time to weight plateau reports average reductions of roughly −13.4%, −14.5%, −14.3% and −13.3% at week 24 across baseline BMI categories, suggesting that at the half-year mark many people are still losing a meaningful amount of weight.

Approaching one year

In real-world practice, the same study found an average of −15.3% at 12 months. In the SURMOUNT-1 trial, in adults with obesity or overweight without diabetes, the mean weight loss at week 72 was −15.0% with 5 mg, −19.5% with 10 mg and −20.9% with 15 mg, compared with −3.1% with placebo. A European regulatory document for the programme confirmed the same order of magnitude at the end of the study, with roughly −16.0%, −21.4% and −22.5% versus −2.4%.

Put another way: when people search for “Mounjaro before and after”, the most accurate picture is not an overnight transformation but a curve that usually starts early and builds over time. If you are interested in the detail of the evidence and how patients describe it alongside the trials, you can go on to read what the trials and patients say about Mounjaro.

Why the pace is not the same for everyone

The studies do not allow anyone to promise an exact month-by-month figure for each person. Your starting point, the maintenance dose you reach, how well you tolerate the dose increases and your clinical circumstances all play a part. So slower weight loss at the start does not on its own mean the treatment will not work, just as a rapid early drop does not define the whole journey.

It is also important to distinguish between trial data and real-world clinical data. Trials provide a more controlled benchmark; real-world practice shows what happens outside that setting, with more variability. Both are useful if read with the right nuance.

What about side effects at the start?

The Spanish SmPC notes that gastrointestinal adverse effects are more common while the dose is being increased and lessen over time. In weight-management studies in people without diabetes, nausea occurred in 24.6% with 5 mg, 33.3% with 10 mg and 31.0% with 15 mg, compared with 9.5% with placebo. Diarrhoea occurred in 18.7%, 21.2% and 23.0% with 5, 10 and 15 mg, compared with 7.3% with placebo.

That pattern fits with what many people describe as the “before and after” of treatment: it is not only weight that changes, but also how each phase is tolerated. To understand this better, it may help to read which side effects can occur with Ozempic and Mounjaro.

What this means in Spain today

Spain is no stranger to this debate. An ENE-COVID study published in 2023 found crude obesity prevalence of 19.3% in men and 18.0% in women, and excess weight prevalence of 63.7% and 48.4% respectively. Against that backdrop, it is no surprise that many online searches try to turn the trials into a very specific question: how long does it take to notice, and what can you realistically expect?

The most honest answer is this: Mounjaro can start to have an effect early on, but the meaningful pattern is measured in months, not days, and the final result cannot be read from the first month. If you are also concerned about what happens when this type of treatment is stopped, you can read why weight comes back after stopping treatment and how it is managed.

Key takeaways

When looking at “Mounjaro before and after”, the most useful thing is not to hunt for a miracle photo but to understand the trajectory: a start in the first few weeks, progress at 3 and 6 months and clearer results as you approach one year, or beyond in the trials. What is available in Spain today is medical weight-loss treatment with a prior assessment, a prescription from a registered doctor where appropriate, and ongoing follow-up. If you would like to know whether this approach suits you, you can check in a few minutes whether you are eligible.